Yang et al. showed that ALDH3A1 is a key metabolic marker upregulated in pancreatic adenocarcinoma patients with new-onset diabetes, contributing to tumor progression, immune suppression, and poor prognosis [41]. This evidence concerns the gene ALDH3A1 and neoplasm.